Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Pain mystery score beliefs: a comparison of fibromyalgia and rheumatoid arthritis.

Ferrari R, Russell AS.

Int J Rheumatol. 2014;2014:593507. doi: 10.1155/2014/593507. Epub 2014 Dec 9.

2.

Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries.

Prankerd RJ, Nguyen TH, Ibrahim JP, Bischof RJ, Nassta GC, Olerile LD, Russell AS, Meiser F, Parkington HC, Coleman HA, Morton DA, McIntosh MP.

PLoS One. 2013 Dec 23;8(12):e82965. doi: 10.1371/journal.pone.0082965. eCollection 2013.

3.

Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee.

Maksymowych WP, Russell AS, Chiu P, Yan A, Jones N, Clare T, Lambert RG.

Arthritis Res Ther. 2012 Oct 4;14(5):R206. doi: 10.1186/ar4044.

4.

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.

Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK.

Ann Rheum Dis. 2011 Oct;70(10):1826-30. doi: 10.1136/ard.2010.139345.

5.

Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial.

Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, Hanley DA, Morrish DW, Maksymowych WP, Rowe BH.

CMAJ. 2008 Feb 26;178(5):569-75. doi: 10.1503/cmaj.070981.

7.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.

Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P.

Ann Rheum Dis. 2007 Feb;66(2):189-94. Epub 2006 Sep 19.

8.

Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.

Russell AS, Maksymowych WP, de Silva M.

Ann Rheum Dis. 2005 Dec;64(12):1807. No abstract available.

9.

A re-examination of the whiplash associated disorders (WAD) as a systemic illness.

Ferrari R, Russell AS, Carroll LJ, Cassidy JD.

Ann Rheum Dis. 2005 Sep;64(9):1337-42. Epub 2005 Feb 24.

10.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H.

Ann Rheum Dis. 2004 May;63(5):508-16.

11.

Opioids and chronic pain.

Russell AS, Aaron SL.

CMAJ. 2003 Oct 28;169(9):902, 904; author reply 904. No abstract available.

12.

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH.

Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii2-9. Review. No abstract available. Erratum in: Ann Rheum Dis. 2004 Jan;63(1):114. Kavenaugh A F [corrected to Kavanaugh A F].

13.

Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

Mayo PR, Skeith K, Russell AS, Jamali F.

Br J Clin Pharmacol. 2000 Dec;50(6):605-13.

14.

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).

Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH.

Ann Rheum Dis. 2000 Nov;59 Suppl 1:i1-2. Review. No abstract available.

15.

Epidemiology of whiplash: an international dilemma.

Ferrari R, Russell AS.

Ann Rheum Dis. 1999 Jan;58(1):1-5. No abstract available.

16.

Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Aviña-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME, Russell AS.

Ann Rheum Dis. 1998 Oct;57(10):582-7.

17.

Ossification of the posterior longitudinal ligament in three geographically and genetically different populations of ankylosing spondylitis and other spondyloarthropathies.

Ramos-Remus C, Russell AS, Gomez-Vargas A, Hernandez-Chavez A, Maksymowych WP, Gamez-Nava JI, Gonzalez-Lopez L, García-Hernández A, Meoño-Morales E, Burgos-Vargas R, Suarez-Almazor ME.

Ann Rheum Dis. 1998 Jul;57(7):429-33.

18.

The art versus the science of medicine. Are clinical practice guidelines the answer?

Suarez-Almazor ME, Russell AS.

Ann Rheum Dis. 1998 Feb;57(2):67-9. No abstract available.

19.

Where's the evidence?

Russell AS, Suarez-Almazor ME.

CMAJ. 1997 Dec 15;157(12):1736-7. No abstract available.

20.

The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis.

Maksymowych WP, Jhangri GS, Gorodezky C, Luong M, Wong C, Burgos-Vargas R, Morenot M, Sanchez-Corona J, Ramos-Remus C, Russell AS.

Ann Rheum Dis. 1997 Aug;56(8):488-92.

Supplemental Content

Loading ...
Support Center